Indications
For the active immunisation of Leishmania-negative dogs from six months of age to reduce the risk to develop an active infection and clinical disease after contact with Leishmania infantum. The efficacy of the vaccine has been demonstrated in dogs submitted to multiple natural parasite exposure in zones with high infection pressure. Onset of immunity: 4 weeks after the primary vaccination course. Duration of immunity: 1 year after the last re-vaccination.
Composition
- Active substance
- Leishmania infantum excreted secreted proteins
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- CaniLeish
- Active substance
- Leishmania infantum excreted secreted proteins
- Group
- Veterinary medicines
- Marketing authorisation holder
- Virbac S.A.